Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma

Berner, Kjetil; Johannesen, Tom Børge; Berner, Aasmund; Haugland, Hans Kristian; Bjerkehagen, Bodil; Bøhler, Per J.; Bruland, Øyvind S.

doi:10.3109/0284186x.2014.923934

Cited by 109 publications

(134 citation statements)

References 21 publications

(64 reference statements)

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…Though there are many advances in the surgical resection and adjuvant chemotherapy for osteosarcoma in recent years, the prognosis for osteosarcoma patients has not been obviously improved [3]. A study from Norway showed that there was no improvement in the overall survival for osteosarcoma since the 1990s, and the survival rates were still poor for elderly people or patients with metastatic diseases [2]. Previous studies have suggested that patients with poor histological response to chemotherapy or advanced stages usually have worse prognosis [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum C-reactive protein and overall survival of patients with osteosarcoma

Tian

Wang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Increased level of serum C-reactive protein (CRP) has been identified as an important prognostic factor in several types of cancers. However, the prognostic significance of serum CRP levels in patients with osteosarcoma was still unclear. A retrospective cohort study of 85 patients was performed to assess the prognostic significance of serum CRP level in osteosarcoma. Both log-rank test and multivariable analysis by Cox regression model were used to assess the impact of serum CRP levels on the overall survival in patients with osteosarcoma. Among those 85 patients, 28 (32.9 %) had high serum CRP level (>1 mg/dL), while the other 57 (67.1 %) patients had normal serum CRP level (≤ 1 mg/dL). There was no obvious difference in the baseline characteristics between high CRP group and normal CRP group. Kaplan-Meier product-limit method showed that patients with high serum CRP levels had significantly poorer overall survival than those patients with normal serum CRP levels (log-rank test P = 0.0008). Multivariable analysis by Cox regression model further showed that high serum CRP level was an independent predictor of poor overall survival (hazard ratio [HR] = 2.39; 95 % confidence interval [95 % CI] 1.22-4.67, P = 0.01). Thus, serum CRP level has an important prognostic significance in patients with osteosarcoma, and high CRP level is associated with worse overall survival.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Osteosarcoma is the most common primary malignant bone tumor [1,2]. Though there are many advances in the surgical resection and adjuvant chemotherapy for osteosarcoma in recent years, the prognosis for osteosarcoma patients has not been obviously improved [3].…”

Section: Introductionmentioning

confidence: 99%

Serum C-reactive protein and overall survival of patients with osteosarcoma

Tian

Wang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…The malignancy of osteosarcoma is high, with an extremely poor patient prognosis. Osteosarcoma often results in pulmonary metastasis within a number of months, with a 3-5 year survival rate of 5-20% (1). Surgery remains the primary treatment option for patients with osteosarcoma; however, the incidence of relapse for these patients is high (1).…”

Section: Introductionmentioning

confidence: 99%

“…Osteosarcoma often results in pulmonary metastasis within a number of months, with a 3-5 year survival rate of 5-20% (1). Surgery remains the primary treatment option for patients with osteosarcoma; however, the incidence of relapse for these patients is high (1). For patients with advanced stage osteosarcoma who have missed the opportunity for surgical therapy, comprehensive treatments, including radiotherapy, chemotherapy and biological agents, have become the main option for therapy (2,3).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of miRNA‑21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN

Miu

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the expression of micro (mi)RNA-21 in osteosarcoma cells, and its role in inhibiting the invasion and metastasis of osteosarcoma. Human osteosarcoma MG-63 cells and osteoblast hFOB1.19 cells were used to compare the expression of miRNA-21 using reverse transcription-quantitative polymerase chain reaction analysis. A miRNA-21 mimic or inhibitor were transfected into the MG-63 cells to upregulate and downregulate the expression of miRNA-21, respectively. The present study investigated the proliferation and invasion of transfected MG-63 cells using MTT and Transwell assays. Western blot analyses were used to investigate the regulation of important proteins in the phosphatase and tensin homolog/phosphoinositide 3-kinase/RAC-α serine/threonine-protein kinase (PTEN/PI3K/AKT) signaling pathway. Compared with hFOB1.19 cells, miRNA-21 expression was significantly upregulated in the MG-63 cells (P<0.01), which lead to increased proliferation. Downregulating miRNA-21 expression reduced the proliferation of MG-63 cells compared with hFOB1.19 cells. Invasion assays and western blot analyses revealed that the overexpression of miRNA-21 significantly enhanced the invasion ability of MG-63 cells and the expression of phosphorylated (p-)AKT, while downregulation of miRNA-21 expression reduced the protein level of AKT and p-AKT. In the MG-63 cells, miRNA-21 upregulation significantly inhibited the protein level of PTEN, resulting in significantly increased AKT and PI3K protein levels (P<0.01). In conclusion, the results of the present study indicate that the expression of miRNA-21, PI3K and AKT is increased in the osteosarcoma cell line MG-63, which results in reduced expression of PTEN and increased expression of proteins in the PI3K/AKT signaling pathway, and thus increases the aggressiveness of osteosarcoma cells.

show abstract

“…Unfortunately, the only time period since then during which significant prognostic gains were achieved was from the late 1970s until the early 1980s, when combining multi-agent chemotherapy with surgery revolutionized treatment 2 . Unfortunately, the decades since have witnessed no further improvements of survival in North America 3 or Europe 4– 6 . Nevertheless, there have been numerous advances in the management of osteosarcoma which merit review and discussion.…”

Section: Introductionmentioning

confidence: 99%

Advances in the management of osteosarcoma

et al. 2016

View full text Add to dashboard Cite

Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward.

show abstract

Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma

Cited by 109 publications

References 21 publications

Serum C-reactive protein and overall survival of patients with osteosarcoma

Serum C-reactive protein and overall survival of patients with osteosarcoma

Inhibition of miRNA‑21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN

Advances in the management of osteosarcoma

Contact Info

Product

Resources

About